Christa Krupski, DO, MPH, on Reinfusion of Tisagenlecleucel in B-ALL


The hematologist/oncologist at Cincinnati Children’s discussed unfavorable outcomes with tisa-cel reinfusion in patients with B-cell acute lymphocytic leukemia.

“The main take home message is that CAR T-cell therapy reinfusion, if it does induce remission or re-induce B-cell aplasia, that window is very short. And it should only be used as a bridge to something like transplant, it will not be successful as a standalone or definitive therapy.”

Investigators from Cincinnati Children’s Hospital studied the use of tisagenlecleucel reinfusion in patients with relapsed B-cell acute lymphocytic leukemia and found that reinfusion did not induce favorable outcomes in these patients and may only have utility as a bridging therapy to other treatment options such as stem cell transplant. These data were presented by investigator Christa Krupski, DO, MPH, hematologist/oncologist, bone marrow transplantation, Cincinnati Children’s, at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19.

CGTLive spoke to Krupski to learn more about the need for this research and the questions that remain to be investigated with reinfusion of a chimeric antigen receptor (CAR) T-cell receptor therapy. She discussed the study conducted and the findings presented at the meeting, which included only short responses if any response in the study participants.

For more coverage of the 2023 Tandem Meetings, click here.

Krupski C, Baggott C, McNerney KO, et al. Outcomes following tisagenlecleucel reinfusion in children and young adults with B-cell acute lymphocytic leukemia. Presented at: 2023 Tandem Meetings, February 15-18, Orlando, Florida. Late-breaker 4.
Related Videos
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
Aimee C. Talleur, MD, a physician at St. Jude Children’s Research Hospital
Pat Furlong, BSN, RN
N. Nora Bennani, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
© 2024 MJH Life Sciences

All rights reserved.